2.96  0.13 (4.59%)		05-16 16:00
Open: 2.93 High: 3.04 Volume: 56,362		Pre. Close: 2.83 Low: 2.84 Market Cap: 6(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

First Wave BioPharma, Inc. is a biopharmaceutical company in the clinical development phase, concentrating on the research and creation of specialized, non-systemic treatments for various gastrointestinal conditions. The company's therapeutic pipeline centers on two main compounds: 1. Niclosamide: An oral small molecule recognized for its antiviral and anti-inflammatory properties. Programs utilizing niclosamide include: FW-COV, currently undergoing Phase II trials for gastrointestinal infections caused by SARS-CoV-2. FW-UP (Phase II) and FW-UC (Phase Ib/IIa), both targeting ulcerative proctitis and ulcerative proctosigmoiditis. FW-ICI-AC, designed to treat colitis and diarrhea linked to immune checkpoint inhibitors in advanced cancer patients. FW-CD, which has successfully completed Phase I clinical trials for Crohn's disease. 2. Adrulipase: A biologic, recombinant lipase enzyme formulated as an oral, non-systemic capsule. Its purpose is to assist in the digestion of fats and other nutrients, with development focused on treating exocrine pancreatic insufficiency (EPI) in patients afflicted with cystic fibrosis and chronic pancreatitis. Originally founded in 2014, the company operated as AzurRx BioPharma, Inc. until it adopted the name First Wave BioPharma, Inc. in September 2021. The firm's headquarters are located in Boca Raton, Florida.

Wed, 02 Sep 2026
First Wave BioPharma Inc. (FWBI) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Thu, 24 Apr 2025
First Wave BioPharma (FWBI) Stock Price, News & Analysis - Stock Titan

Thu, 16 May 2024
First Wave BioPharma Changes Name to Entero Therapeutics - Yahoo Finance

Thu, 14 Mar 2024
Why Is Spruce Biosciences (SPRB) Stock Down 78% Today? - InvestorPlace

Thu, 14 Sep 2023
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi - GlobeNewswire

Thu, 14 Sep 2023
Lowenstein Represents First Wave Biopharma in Exclusive Global License Agreement for Capeserod From Sanofi - Lowenstein Sandler LLP

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date